MedTrace Logo

Timing of Initiation of LMWH Administration in Pregnant Women With APS

NCT02326051 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2017-11-29

No results posted yet for this study

Summary

Evaluation of the effect of altering the timing of initiation of low molecular weight heparin (LMWH) administration on the pregnancy outcomes in women with antiphospholipid syndrome (APS)

Conditions

  • Recurrent Miscarriage
  • Antiphospholipid Syndrome

Interventions

DRUG

Enoxaparin

Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy

DRUG

Enoxaparin

Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy

Sponsors & Collaborators

  • Mohamed Sayed Abdelhafez

    lead OTHER

Principal Investigators

  • Mohamed I Eid, Dr · Mansoura University

  • Mohamed S Abdelhafez, Dr · Mansoura University

  • Waleed El-refaie, Dr · Mansoura University

  • Ahmed El-Zayadi, Dr · Mansoura University

  • Ahmed Badawy, Prof · Mansoura University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
38 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-12-31
Primary Completion
2017-02-28
Completion
2017-05-31

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02326051 on ClinicalTrials.gov